CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.837
EU - Europa 5.955
AS - Asia 2.465
AF - Africa 32
SA - Sud America 27
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 20
Totale 26.357
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.765
GB - Regno Unito 2.102
IT - Italia 1.074
CN - Cina 826
SE - Svezia 628
DE - Germania 590
HK - Hong Kong 465
IE - Irlanda 428
SG - Singapore 417
UA - Ucraina 392
TR - Turchia 324
FI - Finlandia 219
BG - Bulgaria 187
FR - Francia 145
VN - Vietnam 111
IN - India 84
ID - Indonesia 78
CA - Canada 63
JP - Giappone 43
BE - Belgio 31
MY - Malesia 26
EG - Egitto 24
RU - Federazione Russa 24
IQ - Iraq 22
LT - Lituania 22
TW - Taiwan 22
NL - Olanda 19
EU - Europa 17
IR - Iran 17
AU - Australia 15
RO - Romania 15
ES - Italia 14
CH - Svizzera 11
CZ - Repubblica Ceca 11
KR - Corea 11
BR - Brasile 10
NO - Norvegia 8
CL - Cile 7
MX - Messico 6
GH - Ghana 5
MT - Malta 5
NZ - Nuova Zelanda 5
PK - Pakistan 5
PT - Portogallo 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AT - Austria 4
LU - Lussemburgo 4
PH - Filippine 4
AR - Argentina 3
BZ - Belize 3
EC - Ecuador 3
IS - Islanda 3
PL - Polonia 3
BD - Bangladesh 2
IL - Israele 2
KZ - Kazakistan 2
MD - Moldavia 2
MK - Macedonia 2
PE - Perù 2
SI - Slovenia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
BN - Brunei Darussalam 1
DK - Danimarca 1
ET - Etiopia 1
GR - Grecia 1
HR - Croazia 1
LV - Lettonia 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
OM - Oman 1
SK - Slovacchia (Repubblica Slovacca) 1
ZM - Zambia 1
Totale 26.357
Salva come PNG Salva come JPEG
Città #
Fairfield 3.260
Woodbridge 1.816
Southend 1.682
Ashburn 1.493
Houston 1.437
Seattle 1.277
Chandler 1.195
Cambridge 1.028
Wilmington 1.002
Jacksonville 744
Ann Arbor 736
Dearborn 736
Nyköping 473
Hong Kong 462
Dublin 424
Modena 306
Singapore 284
Beijing 275
San Diego 243
Izmir 219
Princeton 188
Sofia 187
Eugene 174
New York 126
Helsinki 108
Dong Ket 103
London 88
Falls Church 85
Jakarta 75
Bremen 63
Fremont 60
Milan 59
Boardman 58
Redwood City 56
Shanghai 54
Ottawa 46
San Giuliano Milanese 36
Phoenix 33
Norwalk 29
Brussels 27
Rome 27
Hefei 26
Bologna 22
Guangzhou 22
Asyut 21
Baghdad 21
Kilburn 20
Tokyo 20
Munich 19
Chiswick 18
Nanjing 18
Kunming 16
Banqiao 14
Florence 14
Jinan 14
Siena 14
Absecon 13
Napoli 13
Des Moines 12
Frankfurt am Main 12
Hounslow 12
Paris 12
Dallas 11
Los Angeles 11
San Mateo 11
Brno 9
Chicago 9
Detroit 9
Fuzhou 9
Indiana 9
Parma 9
Augusta 8
Chengdu 8
Grafing 8
Mountain View 8
Mumbai 8
Shenyang 8
Toronto 8
Wuhan 8
Hanoi 7
Hyderabad 7
Prescot 7
Sassuolo 7
Xian 7
Brooklyn 6
Carpi 6
Edinburgh 6
Genoa 6
Gunzenhausen 6
Hangzhou 6
Istanbul 6
Nanchang 6
Piacenza 6
San Jose 6
San Marco 6
Tappahannock 6
Verona 6
Acri 5
Angera 5
Bangalore 5
Totale 21.406
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 381
GD2 expression in breast cancer. 291
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 268
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 257
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 247
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 247
BRAF ,NRASandC-KITAdvanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival 241
Transient sunitinib resistance in gastrointestinal stromal tumors. 221
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 219
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 217
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 211
M09Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 208
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 204
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 201
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 198
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 197
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 197
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 197
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 193
Quality of life and anxious-depressive symptoms in cancer patients undergoing mindfulness-based interventions: Feasibility and preliminary outcomes on prospective single-centre case-control study (MIND4ME St.) 192
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 192
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 191
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 189
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 189
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma 187
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 187
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 184
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 184
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 184
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 184
5-Fluorouracil pharmacogenomics: still rocking after all these years? 183
Il trattamento di prima e seconda linea nel carcinoma gastrico 180
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 179
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. 178
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 175
The evolving role of microsatellite instability in colorectal cancer: A review 174
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 172
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 172
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 171
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 171
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 170
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma 168
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 167
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 166
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 165
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 164
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 164
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 163
Reply to O. Corli et al and M. Lucchesi et al 163
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 162
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 162
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 162
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 162
Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 161
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. 161
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 160
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 159
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 158
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 156
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 155
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 155
Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy.Current Perspectives and Novel Strategies 155
The Italian Rare Pancreatic Exocrine Cancer Initiative 155
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 154
Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. 153
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 153
Progress of molecular targeted therapies for advanced renal cell carcinoma. 153
Selecting the best treatment for an individual patient. 153
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 153
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 153
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. 152
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 152
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 152
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 151
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 150
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 150
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 150
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 149
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? 149
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 149
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 149
Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. 148
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. 148
State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. 148
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 148
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 148
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 147
Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer 146
Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma 146
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 146
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 146
Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. 145
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. 145
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 145
Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. 144
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. 144
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 144
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 143
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials 141
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 139
Totale 17.412
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.191
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.191
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.372 0 0 0 390 655 1.119 1.063 707 695 271 345 127
2020/20215.407 543 202 445 436 604 469 420 647 307 567 376 391
2021/20223.569 237 431 328 152 98 248 184 192 381 351 654 313
2022/20233.576 418 361 223 319 411 422 54 283 771 44 150 120
2023/20242.059 77 117 116 194 425 121 256 350 43 54 95 211
2024/2025564 276 93 122 73 0 0 0 0 0 0 0 0
Totale 26.703